Cracking Prostate Cancer’s Code: What the STAMPEDE Trial Reveals

STAMPEDE trial is focused on advanced prostate cancer treatments.

Over 12,000 participants have contributed to this research.

Genomic risk scores significantly impact treatment outcomes.

PTEN loss correlates with chemotherapy benefits.

Transcriptomic testing enhances traditional pathology in treatment decisions.

Integrated genomic data can refine patient management strategies.

Future research will explore additional molecular pathways in prostate cancer.